

May 2, 2018



# Pressure BioSciences, Inc., a Leader in the Development & Sale of Pressure-Based Solutions for the Worldwide Life Sciences Market, to Host Webinar Update for Investors

- *Company to Discuss Expected Impact on 2018 Revenue from*
- *Recent Product Enhancements, New Field Salesforce,*
- *BaroFold Technology Asset Acquisition, and Newly Issued Patents*

**SOUTH EASTON, MA / ACCESSWIRE / May 2, 2018** /Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry, today announced that Mr. Richard T. Schumacher, President and CEO of PBI, will host a webinar update and live Q&A session for investors on Wednesday, May 2, 2018, at 3:00 pm EDT. The webinar will include discussions on enhancements made to products in the Company's core Research Products & Services business segment, the Company's new field salesforce, the acquisition of all assets of BaroFold Corporation, and the issuance of patents on the Company's cutting-edge Ultra Shear Technology ("UST") platform. The Company will also offer a brief outlook for the 2018 fiscal year.

RedChip's Global Online Growth Conference brings together investors and executives of leading small-cap companies, representing a broad spectrum within the small cap sector. More than 10,000 investors attend RedChip's Online Growth Conference series each year. No registration is required to participate in the conference. Start times are subject to change.

To view the webinar, please visit: <https://www.redchip.com>.

## **About Pressure BioSciences, Inc.**

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or "PCT") hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently

acquired PreEMT technology from BaroFold, Inc. to allow immediate entry into the biologics contract research services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology ("UST") platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

<http://www.pressurebiosciences.com>

### **Forward Looking Statements**

Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2017, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following link:

<http://www.pressurebiosciences.com>

Please visit us on Facebook, LinkedIn, and Twitter.

### **Investor Contacts:**

Richard T. Schumacher, President & CEO, PBI (T) 508-230-1828

Victor Roberts, RedChip Companies (T) 407-644-4256 (111)

[victor@redchip.com](mailto:victor@redchip.com)

**SOURCE:** Pressure BioSciences, Inc.